{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:Q9P2X3",
      "entity_text" : "impact",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:82146",
      "entity_text" : "Bexarotene",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Promising initial clinical trials of a retinoid X receptor agonist, Bexarotene, further supports that modulation of retinoid signalling can have a clinically significant impact on schizophrenia symptoms [XREF_BIBR, XREF_BIBR].",
  "reading_complete" : "2020-08-08T17:58:53Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-08T17:54:54Z",
  "trigger" : "supports",
  "evidence" : [ "Bexarotene, further supports that modulation of retinoid signalling can have a clinically significant impact" ],
  "pmc_id" : "7156344",
  "score" : 0
}